DE60035032D1 - Verwendung von pioglitazone zur verbesserung der ketose und der azidose - Google Patents

Verwendung von pioglitazone zur verbesserung der ketose und der azidose

Info

Publication number
DE60035032D1
DE60035032D1 DE60035032T DE60035032T DE60035032D1 DE 60035032 D1 DE60035032 D1 DE 60035032D1 DE 60035032 T DE60035032 T DE 60035032T DE 60035032 T DE60035032 T DE 60035032T DE 60035032 D1 DE60035032 D1 DE 60035032D1
Authority
DE
Germany
Prior art keywords
ketosis
azidosis
pioglitazone
improvement
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035032T
Other languages
English (en)
Other versions
DE60035032T2 (de
Inventor
Hiroyuki Odaka
Masami Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE60035032D1 publication Critical patent/DE60035032D1/de
Application granted granted Critical
Publication of DE60035032T2 publication Critical patent/DE60035032T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60035032T 1999-04-14 2000-04-13 Verwendung von pioglitazone zur verbesserung der ketose und der azidose Expired - Lifetime DE60035032T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP10711999 1999-04-14
JP10711999 1999-04-14
PCT/JP2000/002413 WO2000061127A2 (en) 1999-04-14 2000-04-13 Use of insulin sensitisers for improving ketosis

Publications (2)

Publication Number Publication Date
DE60035032D1 true DE60035032D1 (de) 2007-07-12
DE60035032T2 DE60035032T2 (de) 2008-01-24

Family

ID=14450976

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035032T Expired - Lifetime DE60035032T2 (de) 1999-04-14 2000-04-13 Verwendung von pioglitazone zur verbesserung der ketose und der azidose

Country Status (14)

Country Link
US (2) US6677363B1 (de)
EP (1) EP1169037B1 (de)
KR (1) KR100697582B1 (de)
CN (1) CN1222289C (de)
AT (1) ATE363280T1 (de)
AU (1) AU3677900A (de)
CA (1) CA2369694C (de)
DE (1) DE60035032T2 (de)
ES (1) ES2283291T3 (de)
HU (1) HUP0201653A3 (de)
NO (1) NO20014935L (de)
PL (1) PL352021A1 (de)
TW (1) TWI249401B (de)
WO (1) WO2000061127A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
PL356745A1 (en) * 1999-11-10 2004-06-28 Takeda Chemical Industries, Ltd Body weight gain inhibitors
WO2001058491A1 (fr) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Medicament comprenant une combinaison
GB0027783D0 (en) * 2000-11-14 2000-12-27 S P A Novel use
EP1354602B1 (de) 2000-12-26 2006-10-04 Sankyo Company, Limited Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
US20030045553A1 (en) 2001-04-04 2003-03-06 Bussolari Jacqueline C. Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
ATE442148T1 (de) 2001-04-04 2009-09-15 Ortho Mcneil Janssen Pharm Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
DE60237594D1 (de) * 2001-04-25 2010-10-21 Takeda Pharmaceutical Verwendung des abc-expressionspromotors pioglitazon zur behandlung von arteriosklerose obliterans
EP1461070B1 (de) * 2001-12-29 2007-01-24 Novo Nordisk A/S Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors
EP1688148A1 (de) * 2002-12-03 2006-08-09 Novo Nordisk A/S Behandlung mit Kombinationspräparaten aus Exendin-4 und Thiazolidindionen
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP2976073B1 (de) * 2013-03-19 2019-08-28 University Of South Florida Zusammensetzungen und verfahren zur herstellung erhöhter und verzögerter ketose
US10596130B2 (en) 2017-12-19 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973792B2 (en) 2019-02-13 2021-04-13 Axcess Global Sciences, Llc Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use
US10596129B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10973786B2 (en) 2016-03-11 2021-04-13 Axcess Global Sciences, Llc R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions
US10736861B2 (en) 2016-03-11 2020-08-11 Axcess Global Sciences, Llc Mixed salt compositions for producing elevated and sustained ketosis
US11185518B2 (en) 2017-12-19 2021-11-30 Axcess Global Sciences, Llc S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US10245242B1 (en) 2017-11-22 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10596131B2 (en) 2017-11-22 2020-03-24 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US10245243B1 (en) 2017-12-19 2019-04-02 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
BR112019003006A2 (pt) * 2016-08-17 2019-05-14 Support-Venture Gmbh uso de uma combinação farmacêutica e kit para prevenir ou tratar perda auditiva
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
WO2019154893A1 (en) * 2018-02-08 2019-08-15 Strekin Ag Oral extended release pharmaceutical compositions for preventing or treating hearing loss
US10980772B2 (en) 2018-08-27 2021-04-20 Axcess Global Sciences, Llc Compositions and methods for delivering tetrahydrocannabinol and ketone bodies
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11129802B2 (en) 2018-08-27 2021-09-28 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US10512615B1 (en) 2018-08-27 2019-12-24 Axcess Global Sciences, Llc Compositions and methods for delivering cannabidiol and ketone bodies
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US11241401B2 (en) 2020-02-06 2022-02-08 Axcess Global Sciences, Llc Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions
KR102180524B1 (ko) * 2018-11-16 2020-11-18 순천대학교 산학협력단 반추동물의 산독증 예방용 완충제 조성물
US11033553B2 (en) 2019-06-21 2021-06-15 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
DE69530094T2 (de) * 1994-08-10 2004-01-29 Takeda Chemical Industries Ltd Thiazolidindione derivate, ihre herstellung und verwendung
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JPH09323930A (ja) 1996-04-04 1997-12-16 Takeda Chem Ind Ltd 悪液質の予防・治療剤
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
AR029876A1 (es) * 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
CN1305376A (zh) * 1998-06-30 2001-07-25 武田药品工业株式会社 治疗糖尿病的药物组合物
TWI249401B (en) * 1999-04-14 2006-02-21 Takeda Chemical Industries Ltd Agent for improving ketosis
EP1305285B1 (de) * 2000-07-25 2007-05-16 Merck & Co., Inc. N-substituierte indole mit anwendung in der behandlung von diabetes

Also Published As

Publication number Publication date
CA2369694A1 (en) 2000-10-19
PL352021A1 (en) 2003-07-14
US7595333B2 (en) 2009-09-29
TWI249401B (en) 2006-02-21
WO2000061127A3 (en) 2001-09-07
NO20014935L (no) 2001-12-12
KR100697582B1 (ko) 2007-03-22
HUP0201653A3 (en) 2004-12-28
AU3677900A (en) 2000-11-14
ES2283291T3 (es) 2007-11-01
NO20014935D0 (no) 2001-10-10
ATE363280T1 (de) 2007-06-15
EP1169037B1 (de) 2007-05-30
CN1347319A (zh) 2002-05-01
KR20010108497A (ko) 2001-12-07
WO2000061127A2 (en) 2000-10-19
EP1169037A2 (de) 2002-01-09
CA2369694C (en) 2011-01-04
DE60035032T2 (de) 2008-01-24
US6677363B1 (en) 2004-01-13
US20040106649A1 (en) 2004-06-03
HUP0201653A2 (en) 2002-09-28
CN1222289C (zh) 2005-10-12

Similar Documents

Publication Publication Date Title
DE60035032D1 (de) Verwendung von pioglitazone zur verbesserung der ketose und der azidose
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
RS20060320A (en) Substituted indazole-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
DK1112275T3 (da) Hidtil ukendte heteroaromatiske inhibitorer for fructose-1,6-bisphosphatase
UA86042C2 (en) Substituted indazole-o-glucosides
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
DE69939864D1 (de) Ppar-gamma modulatoren
PL354976A1 (en) Factor ix/factor ixa antibodies and antibody derivatives
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
ATE247726T1 (de) Gezielte elektrochemische reduktion von halogenierten 4-amino-picolinsäuren
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
ATE288922T1 (de) Bestimmte heteroaryl substituierte thiol inhibitoren von endothelin wechselnden enzymen
DE60008400D1 (de) Triazolopyrimidinderivate
ATE404602T1 (de) Wässrige polyurethanzubereitungen
ATE320422T1 (de) Metalloproteinase inhibitoren
EP1476149A4 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
DK1244643T3 (da) Tryptaseinhibitorer
PT1244614E (pt) Inibidores de triptase
DE50008241D1 (de) Metallschaumkörper auf basis von zink
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
ID27656A (id) Turunan azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya
AR023895A1 (es) Nuevos derivados de 6-amino-uracilo, su preparacion y su utilizacion
ITTO20011200A0 (it) Procedimento e apparato di ricezione di segnali radio, particolarmente di tipo numerico multi-portante.
ATE334215T1 (de) Verwendung des aminoglycosidresistenzgens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition